ArticleFrontiers in genetics2025
Integrin factor (FAM27E3), as a metastatic marker of papillary thyroid carcinoma, through the p53 signaling pathway promoting lymph node metastasis.
Article in Frontiers in genetics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- PTM-Related Signatures Predict Lymph Node Metastasis and Shape Microenvironment in Hepatocellular Carcinoma: A Single-Cell and Bulk Integrated Analysis.Journal of hepatocellular carcinoma · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Papillary thyroid carcinoma (PTC) has a lymph node metastasis rate of 20%-90%. This study aims to explore the role and regulatory mechanism of the FAM27E3 in PTC lymph node metastasis. Method: The seven thyroid cancer (THCA) datasets from the Gene Expression Omnibus (GEO) were combined as the training group, while the PTC dataset served as the testing group. Venn analysis identified overlapping genes through consistent cluster analysis and weighted gene co-expression network analysis (WGCNA). We used the Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) databases to perform gene set enrichment analysis (GSEA) to explore the enriched terms. Least absolute shrinkage and selection operator (LASSO) analysis was applied to the overlapping genes to identify key influence factors. Finally, FAM27E3 was used for score analysis (epithelial-mesenchymal transition (EMT), angiogenesis, and mRNAsi scores). Immune cell infiltration was assessed using the CIBERSORT algorithm. CCK8, colony formation, Transwell assays, Western blotting, and RT-PCR were employed to evaluate cell viability, invasion, migration, and gene/protein expression. Results: The clustering method distinguished the samples into two subtypes. We obtained the mRNA expression levels of 128 overlapping genes from the tumor and C1 modules of the GSE60542 dataset. FAM27E3 was identified as a hub gene associated with PTC lymph node metastasis and had a significantly positive correlation with EMT_score. The MRNAsi_score was increased in the FAM27E3 high-expression group. A high expression of FAM27E3 indicated a reduction in the overall macrophage levels. FAM27E3 exhibited high expression in PTC cell lines, and its downregulation suppressed cell proliferation, migration, and invasion. FAM27E3 promoted the lymph node metastasis of PTC, which was associated with the p53 signaling pathway. Conclusion: FAM27E3, as a marker for PTC lymph node metastasis, promotes PTC lymph node metastasis related to the p53 signaling pathway.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.